{"id":42119,"date":"2025-09-23T16:11:36","date_gmt":"2025-09-23T08:11:36","guid":{"rendered":"https:\/\/flcube.com\/?p=42119"},"modified":"2025-09-23T16:11:37","modified_gmt":"2025-09-23T08:11:37","slug":"genrix-bio-secures-exclusive-deal-for-vecantoxatug-and-silevimig-with-cms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42119","title":{"rendered":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS"},"content":{"rendered":"\n<p>China\u2011based <strong>Chongqing Genrix Bio Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688443:SHA\">SHA: 688443<\/a>) and <strong>China Medical System Holdings Ltd.<\/strong> (CMS; <a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/8A8:SGX\">SGX: 8A8<\/a>) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: <strong>Vecantoxatug (GR2001)<\/strong> and <strong>Silevimig (GR1801)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-agreements-overview\">Agreements Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Genrix Bio<\/th><th>CMS<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D &amp; Production<\/strong><\/td><td>Full responsibility in China<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Commercialization<\/strong><\/td><td>Mainland China only<\/td><td>Mainland China + APAC (ex\u2011China), Middle East &amp; North Africa<\/td><\/tr><tr><td><strong>Regulatory<\/strong><\/td><td>NMPA registration in China<\/td><td>NMPA registration + overseas filings<\/td><\/tr><tr><td><strong>Financials<\/strong><\/td><td>Up to RMB\u202f510\u202fmillion in upfront &amp; milestone payments<\/td><td>Promotion service fees based on China sales<\/td><\/tr><tr><td><strong>Revenue Sharing<\/strong><\/td><td>Mainland sales revenue + supply revenue from non\u2011China regions<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-genrix-bio-s-role\">Genrix Bio\u2019s Role<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Leadership<\/strong> \u2013 Drives pre\u2011clinical and clinical development of GR2001 and GR1801.<\/li>\n\n\n\n<li><strong>Manufacturing Hub<\/strong> \u2013 Owns GMP facilities in Chongqing, ensuring supply chain control.<\/li>\n\n\n\n<li><strong>Regulatory Champion<\/strong> \u2013 Secured Breakthrough Therapy Designation for GR2001 and NDA approvals for both products in China.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cms-s-role\">CMS\u2019s Role<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Engine<\/strong> \u2013 Manages all sales, marketing and distribution activities across China and selected overseas markets.<\/li>\n\n\n\n<li><strong>Regional Expansion<\/strong> \u2013 Leverages existing APAC, Middle East &amp; North Africa networks to accelerate global uptake.<\/li>\n\n\n\n<li><strong>Revenue\u2011Based Fees<\/strong> \u2013 Pays Genrix Bio promotion service fees tied to domestic sales performance.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-highlights\">Product Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vecantoxatug-gr2001\">Vecantoxatug (GR2001)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Recombinant humanized monoclonal antibody that binds the C\u2011terminus of the tetanus toxin heavy chain, blocking neuronal entry and providing passive protection.<\/li>\n\n\n\n<li><strong>Regulatory Milestones<\/strong> \u2013 BTD listing by China\u2019s CDE (May\u202f2024); NDA for tetanus passive immunization accepted (May\u202f2025).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-silevimig-gr1801\">Silevimig (GR1801)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Fully human bispecific antibody targeting the rabies virus envelope G protein (epitopes\u202fI\/III), preventing neural invasion before active vaccine immunity develops.<\/li>\n\n\n\n<li><strong>Regulatory Milestones<\/strong> \u2013 First bispecific antibody for rabies passive immunization; NDA accepted (Jan\u202f2025) for adult exposure; Phase\u202f3 trial underway for pediatric exposure (2\u2011&lt;18\u202fyrs).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tetanus &amp; Rabies Burden<\/strong> \u2013 China remains a high\u2011risk region for both diseases; passive\u2011immunization agents can fill a critical unmet need.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 Dual\u2011antibody formats and quick\u2011action mechanisms differentiate Genrix Bio\u2019s portfolio from existing antitoxins.<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> \u2013 With a projected RMB\u202f510\u202fmillion upfront, the partnership positions both companies to capitalize on a growing global demand for rapid\u2011response biologics.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\">Conclusion<\/h2>\n\n\n\n<p>The Genrix Bio\u2011CMS partnership combines Genrix Bio\u2019s scientific expertise and regulatory traction with CMS\u2019s expansive commercial network, setting the stage for accelerated market entry of Vecantoxatug and Silevimig across China and beyond.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":42120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[3000,844,28,4256,877],"class_list":["post-42119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-genrix-biopharmaceutical","tag-hkg-0867","tag-multi-specific-antibodies","tag-sgx-8a8","tag-sha-688443"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd. (CMS; HKG: 0867, SGX: 8A8) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: Vecantoxatug (GR2001) and Silevimig (GR1801).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42119\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd. (CMS; HKG: 0867, SGX: 8A8) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: Vecantoxatug (GR2001) and Silevimig (GR1801).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42119\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T08:11:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T08:11:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS\",\"datePublished\":\"2025-09-23T08:11:36+00:00\",\"dateModified\":\"2025-09-23T08:11:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2313.webp\",\"keywords\":[\"Genrix Biopharmaceutical\",\"HKG: 0867\",\"Multi-specific antibodies\",\"SGX: 8A8\",\"SHA: 688443\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42119#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42119\",\"name\":\"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2313.webp\",\"datePublished\":\"2025-09-23T08:11:36+00:00\",\"dateModified\":\"2025-09-23T08:11:37+00:00\",\"description\":\"China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd. (CMS; HKG: 0867, SGX: 8A8) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: Vecantoxatug (GR2001) and Silevimig (GR1801).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42119\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2313.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2313.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42119#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd. (CMS; HKG: 0867, SGX: 8A8) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: Vecantoxatug (GR2001) and Silevimig (GR1801).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42119","og_locale":"en_US","og_type":"article","og_title":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS","og_description":"China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd. (CMS; HKG: 0867, SGX: 8A8) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: Vecantoxatug (GR2001) and Silevimig (GR1801).","og_url":"https:\/\/flcube.com\/?p=42119","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-23T08:11:36+00:00","article_modified_time":"2025-09-23T08:11:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42119#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42119"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS","datePublished":"2025-09-23T08:11:36+00:00","dateModified":"2025-09-23T08:11:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42119"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42119#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp","keywords":["Genrix Biopharmaceutical","HKG: 0867","Multi-specific antibodies","SGX: 8A8","SHA: 688443"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42119#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42119","url":"https:\/\/flcube.com\/?p=42119","name":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42119#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42119#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp","datePublished":"2025-09-23T08:11:36+00:00","dateModified":"2025-09-23T08:11:37+00:00","description":"China\u2011based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd. (CMS; HKG: 0867, SGX: 8A8) have inked exclusive cooperation agreements covering the research\u2011development, registration, production and commercialization of two next\u2011generation passive\u2011immunization agents: Vecantoxatug (GR2001) and Silevimig (GR1801).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42119#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42119"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42119#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp","width":1080,"height":608,"caption":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42119#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2313.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42119"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42119\/revisions"}],"predecessor-version":[{"id":42121,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42119\/revisions\/42121"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42120"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}